JPMorgan Chase Reports 5.2% Passive Stake in Neurocrine Biosciences

Overview & Ownership Summary

On October 15, 2026, JPMorgan Chase & Co. filed Amendment No. 2 to Schedule 13G with the SEC regarding its holdings in Neurocrine Biosciences, Inc. (NBIX) as of the event date of September 30, 2026.

• Security: Common Stock, $0.001 par value (CUSIP: 64125C109)
• Aggregate Beneficial Ownership: 5,300,390 shares
• Ownership Percentage: 5.2% of the outstanding class
• Filing Rule: Rule 13d-1(b) (Passive institutional holding company)

Voting and Dispositive Authority

• Sole Voting Power: 4,725,485 shares
• Shared Voting Power: 22,400 shares
• Sole Dispositive Power: 5,294,407 shares
• Shared Dispositive Power: 665 shares

Reporting Subsidiaries

The shares are held through various operating subsidiaries, including:

• J.P. Morgan Trust Company of Delaware
• J.P. Morgan Securities LLC
• JPMorgan Asset Management (UK) Limited
• JPMorgan Chase Bank, National Association
• J.P. Morgan Investment Management Inc.
• J.P. Morgan Mansart Management Limited
• J.P. Morgan Wealth Management Solutions Inc.
• 55I, LLC

Market Impact & Significance

This filing represents a routine amended disclosure by a passive institutional holding company (HC) under Rule 13d-1(b). The certification confirms that the securities were acquired and are held in the ordinary course of business without the purpose or effect of altering or influencing control of the issuer. Consequently, trading significance is assessed as Low.